Caribou Biosciences, Inc.
CRBU
$1.84
-$0.07-3.67%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.66% | -19.00% | -72.45% | -70.31% | -71.01% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.66% | -19.00% | -72.45% | -70.31% | -71.01% |
| Cost of Revenue | -23.63% | -14.40% | 0.71% | -26.55% | -42.45% |
| Gross Profit | 30.10% | 13.42% | -80.51% | -0.23% | 29.76% |
| SG&A Expenses | -18.39% | -12.84% | -11.18% | -5.99% | 20.79% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.57% | -11.74% | -5.79% | 5.53% | 17.32% |
| Operating Income | 18.26% | 11.24% | -9.80% | -24.88% | -43.56% |
| Income Before Tax | 0.29% | -6.23% | -33.29% | -28.51% | -46.37% |
| Income Tax Expenses | -6,011.11% | -104.66% | -104.66% | -104.66% | -104.66% |
| Earnings from Continuing Operations | 0.66% | -6.08% | -33.07% | -28.29% | -46.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 0.66% | -6.08% | -33.07% | -28.29% | -46.08% |
| EBIT | 18.26% | 11.24% | -9.80% | -24.88% | -43.56% |
| EBITDA | 18.53% | 11.89% | -9.49% | -25.02% | -44.57% |
| EPS Basic | 3.83% | -2.72% | -28.60% | -11.68% | -14.03% |
| Normalized Basic EPS | 11.38% | 5.04% | -19.39% | -11.83% | -14.20% |
| EPS Diluted | 3.83% | -2.72% | -28.60% | -11.68% | -14.03% |
| Normalized Diluted EPS | 11.38% | 5.04% | -19.39% | -11.83% | -14.20% |
| Average Basic Shares Outstanding | 3.40% | 3.24% | 4.40% | 12.91% | 22.54% |
| Average Diluted Shares Outstanding | 3.40% | 3.24% | 4.40% | 12.91% | 22.54% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |